Inactive Instrument

Press Releases Neothetics Inc Nasdaq

Equities

US64066G1013

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Evofem Strengthens Phexxi Intellectual Property with New Composition of Matter Patent From USPTO	Apr. 18	PR
Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023	Mar. 27	PR
Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-Cal	Mar. 20	PR
Evofem Biosciences - For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy	Mar. 08	AQ
Washington State HCA Removes Prior Authorization for Hormone-Free "In the Moment" Contraceptive PHEXXI Ahead of Huskies vs. Wolverines Championship Game	Jan. 08	PR
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVLY, EVFM, AEZS, HOLI	Dec. 19	PR
EVOFEM BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Evofem Biosciences, Inc. - EVFM	Dec. 18	BU
Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi, the First and Only FDA-Approved Hormone-Free Contraceptive Gel	Dec. 13	AQ
Shareholder Alert: Ademi LLP investigates whether Evofem Biosciences, Inc. has obtained a Fair Price in its transaction with Aditxt	Dec. 12	PR
EVFM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Evofem Biosciences, Inc. Is Fair to Shareholders	Dec. 12	BU
Evofem Biosciences Announces Financial Results for the Third Quarter of 2023	Nov. 14	PR
Evofem Biosciences : Presentation	Nov. 01	PU
OTC Stocks News-Based Catalyst Watchlist (IMRFF, BLFR, NILIF, EVFM)	23-10-25	AQ
Evofem Biosciences : EVFM at a Glance	23-10-24	PU
Evofem Biosciences Announces Preliminary Results for the Third Quarter of 2023	23-10-24	PR
Evofem Announces Padagis Will Not Seek FDA Approval to Market a Generic Version of Phexxi until Evofem's Phexxi Patents Expire	23-09-28	AQ
Evofem Announces Padagis Will Not Seek FDA Approval to Market a Generic Version of Phexxi® Until Evofem's Phexxi Patents Expire	23-09-27	PR
Evofem Biosciences Successfully Amends S.P.A. with Institutional Investor	23-09-11	PR
Evofem Biosciences' : Proxy for 14 September 2023 Annual Meeting of Stockholders	23-08-29	PU
Evofem Biosciences Signs Non-Binding Letter of Intent to Enable Listing on a National Stock Exchange	23-08-22	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Neothetics Inc Nasdaq

Equities

US64066G1013

Press Releases

Filters